Although a recent clinical trial with MEK162, a potent MEK inhibitor, has shown some activity in patients with NRAS mutant melanoma (Ascierto PA et al.), innate or acquired tumor resistance to single-targeted agents is inevitable. This evidence concerns the gene MAP2K7 and neoplasm.